Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.500

-5.6%

1:30 PM EST

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Mike McFarland who wrote ()	4/6/2000 1:31:00 PM
From: Mike McFarland	Read Replies (1) of 368

TWST: Give us a brief overview of Sangamo BioSciences archive.twst.com (snip) The approach that we have taken is to utilize a specific class of transcription factors known as zinc finger DNA binding proteins, or "ZFPs", which are, based upon the way they recognize DNA, amenable to rational design or genetic engineering. By engineering individual zinc fingers we can cause them to recognize new sequences of DNA in a highly specific manner. We then link these engineered zinc finger protein domains with functional domains that permit us to either activate or repress a target gene. We can fundamentally control the expression of genes in any host system, including human, plant, or microbes with this technology. The company was founded in 1995 with intellectual property from four academic institutions, Johns Hopkins University, Massachusetts Institute of Technology, The Scripps Research Institute, and the Medical Research Council.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext